ORUKA THERAPEUTICS INC

Oruka Therapeutics is a biotechnology company whose primary asset, ORKA-001, is a monoclonal antibody therapeutic for plaque psoriasis. The development of such biologic drugs requires extensive animal testing in preclinical stages to assess safety, efficacy, and pharmacokinetics before human trials can begin. As a clinical-stage company, Oruka’s pipeline is built on this foundational research involving animals.

While specific, publicly available details of Oruka's animal testing protocols are limited in SEC filings, the company’s reliance on standard biopharmaceutical development pathways indicates the use of animal models. The company’s merger and transition into clinical trials does not negate the animal testing that was necessary to reach that stage. This places Oruka within the broad category of commercial animal exploitation common to the biotech and pharmaceutical sectors.